Experimental Drug Delays Progression of Ovarian Cancer

by Kathy Jones on  May 19, 2011 at 5:00 PM Cancer News   - G J E 4
A new study which will be presented at the American Society of Clinical Oncology in Chicago next month has shown that a new experimental drug developed by AstraZeneca delays the progress of ovarian cancer significantly.
 Experimental Drug Delays Progression of Ovarian Cancer
Experimental Drug Delays Progression of Ovarian Cancer

Known as olaparib, the new drug almost doubled the progression free time of the cancer compared to a placebo in the phase II trial. Those women who were given 400 milligrams of olaparib twice a day saw their progression free time increase to 8.4 months before the cancer resurfaced compared to 4.8 months on a placebo.

Lead researcher Dr Jonathan Ledermann said that the drug will now undergo wider trials though he added that patients experienced side effects including nausea, fatigue, vomiting and anemia.

"A well-tolerated antitumor agent that could be used for months or perhaps years as maintenance therapy after standard chemotherapy could be a big step forward and ultimately extend survival", Dr Ledermann added.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
Almost all drugs have undesirable side effects. It's great that there is a drug that can delay the progression of ovarian cancer. Hopefully, it will be a success in wider clinical trials.
ennairam_23 Thursday, May 19, 2011

You May Also Like

View All